Gene therapy, ophthalmology research, and biotechnology innovation by Ocugen
Ocugen introduces master regulator gene approach in novel blindness treatment initiative
Ocugen has introduced a novel modifier gene therapy based on master regulator genes, aiming to influence multiple gene networks to address major blindness diseases. The company highlighted the ...
Ocugen to present 3Q 2026 financial results on November 4
Ocugen has announced it will release its third quarter 2026 financial results on Wednesday, November 4, at 8:30 a.m. Eastern Time. The company will host a conference call and webcast to provide a ...
Ocugen moves OCU410 gene therapy for geographic atrophy into Phase 3 trial
Ocugen has announced that its investigational gene therapy, OCU410, is now in Phase 3 clinical trials for the treatment of geographic atrophy, an advanced form of dry age-related macular ...
Ocugen and Roots Pharmaceutical agree to up to 259 million dollar OCU400 licensing deal in MENA
Ocugen has finalized a licensing agreement with Roots Pharmaceutical for its OCU400 gene therapy in the MENA region. The deal includes up to 4 million dollars in upfront and early development ...
Jolanda Crombach named general manager as Ocugen expands European operations
Ocugen has appointed Jolanda Crombach, MSc PharmD, as the general manager of its newly established European affiliate, which will be headquartered in Amsterdam. The move supports three Phase 3 ...
Ocugen to present novel gene therapy platform at major 2026 ophthalmology conferences
Ocugen announced it will present its novel modifier gene therapy platform at several key scientific conferences in 2026, including the EIS 2026, the 26th EURETINA Congress, and the AAO Annual ...
OCU400 available through commercial expanded access in the Bahamas, Ocugen outlines
Ocugen is facilitating access to OCU400 for patients with retinitis pigmentosa in the Bahamas through an Expanded Access Program that allows commercial pricing. The initiative is supported by the ...
Ocugen receives provisional approval for OCU400 gene therapy in the Bahamas
Ocugen announced that its gene therapy candidate OCU400 for retinitis pigmentosa has received provisional approval and priority designation from the LARTA Board in the Bahamas. This regulatory ...
Ocugen brings state lawmakers to its facility to review biotech initiatives
Ocugen announced it hosted Pennsylvania State Representatives Borowski and Friel at its facility this week, engaging directly with CEO Dr. Shankar Musunuri and the company team. During the ...
Ocugen appoints Beth Scott as VP to lead clinical development strategy
Ocugen has appointed Beth Scott as Vice President and Head of Clinical Development, leveraging her three decades of ophthalmology expertise. Scott will lead efforts in retinal clinical ...
Ocugen, Inc. examines RORα as a novel multi-pronged approach to Alzheimer
Ocugen, Inc. has unveiled new research exploring RORα as a potential multi-pathway target in Alzheimer disease treatment. The study, published in Frontiers in Neuroscience, evaluates the role ...
Ocugen, Inc. draws attention to impact of geographic atrophy on retinal health
Ocugen, Inc. is raising awareness about the importance of retinal health and the potential impact of geographic atrophy, a severe eye condition that can lead to vision loss. The company ...
OCU410 Phase 3 progress and RMAT status drive Ocugen, Inc. commercial push
Ocugen, Inc. reported several major milestones during its latest earnings call, with CEO Dr. Shankar Musunuri announcing a 130 million dollar financing deal for the second quarter of 2026. The ...
Ocugen, Inc. shares clinical trial journey of OCU400 participant in fight against retinitis pigmentosa
Ocugen, Inc. has featured the personal account of Manny, an OCU400 clinical trial participant, in the latest story from Fighting Blindness. Manny describes how living with retinitis pigmentosa ...
Ocugen, Inc. targets next generation brain gene therapies with new delivery approaches
Ocugen, Inc. is shedding light on emerging barriers and solutions in the field of brain-targeted gene therapies. In a recent publication in Molecular Therapy, Chief Scientific Officer Dr. Upadhyay ...
Ocugen, Inc. advances ArMaDa study toward Phase 3 in geographic atrophy gene therapy
Ocugen, Inc. moves forward with its ArMaDa Phase 2 study, targeting a transition toward Phase 3 development of OCU410, a gene therapy candidate for geographic atrophy. Arshad M. Khanani, MD, MA, ...
Ocugen, Inc. and Roots Pharmaceutical sign strategic agreement for global gene therapy distribution
Ocugen, Inc. has entered into a binding term sheet with Roots Pharmaceutical to lay the groundwork for expanding global access to innovative gene therapies in the MENA region. The collaboration ...
Ocugen, Inc. advances OCU410 for geographic atrophy affecting 2–3 million patients
Ocugen, Inc. is focusing on advancing OCU410, its investigational therapy for geographic atrophy, an advanced form of dry age-related macular degeneration (AMD) that affects an estimated 2–3 ...
Ocugen, Inc. pursues gene therapy innovation to address rare vision loss conditions
Ocugen, Inc. is taking significant steps to address rare retinal diseases linked to genetic mutations by developing modifier gene therapies. The company’s approach focuses on tackling the ...
Ocugen, Inc. patient experiences vision adaptation after OCU400 clinical trial
A patient living with retinitis pigmentosa for 31 years reports noticeable adaptation to light and darkness following participation in Ocugen, Inc.'s OCU400 clinical trial. Nancy’s personal ...
Ocugen, Inc. leadership drives focus on innovative gene therapies at industry summit
Ocugen, Inc. participated in this year’s Clinical Trials at the Summit, where its Chairman, CEO, and Co-Founder Dr. Shankar Musunuri joined a panel of industry leaders to address inherited ...
